Announcement • Jun 03
BML, Inc. to Report Q1, 2027 Results on Aug 07, 2026 BML, Inc. announced that they will report Q1, 2027 results on Aug 07, 2026 Reported Earnings • May 15
Full year 2026 earnings: EPS exceeds analyst expectations Full year 2026 results: EPS: JP¥204 (up from JP¥161 in FY 2025). Revenue: JP¥150.3b (up 4.9% from FY 2025). Net income: JP¥7.75b (up 24% from FY 2025). Profit margin: 5.2% (up from 4.4% in FY 2025). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 3.8%. Revenue is forecast to grow 3.5% p.a. on average during the next 3 years, compared to a 3.6% growth forecast for the Healthcare industry in Japan. Over the last 3 years on average, earnings per share has fallen by 22% per year but the company’s share price has increased by 4% per year, which means it is well ahead of earnings. Announcement • May 13
BML, Inc., Annual General Meeting, Jun 26, 2026 BML, Inc., Annual General Meeting, Jun 26, 2026. Announcement • May 09
BML, Inc. to Report Fiscal Year 2026 Results on May 13, 2026 BML, Inc. announced that they will report fiscal year 2026 results on May 13, 2026 Upcoming Dividend • Mar 23
Upcoming dividend of JP¥60.00 per share Eligible shareholders must have bought the stock before 30 March 2026. Payment date: 30 June 2026. Payout ratio is a comfortable 56% and this is well supported by cash flows. Trailing yield: 3.0%. Lower than top quartile of Japanese dividend payers (3.6%). Higher than average of industry peers (2.7%). Major Estimate Revision • Mar 04
Consensus EPS estimates increase by 15% The consensus outlook for earnings per share (EPS) in fiscal year 2026 has improved. 2026 revenue forecast increased from JP¥148.0b to JP¥151.0b. EPS estimate increased from JP¥171 to JP¥196 per share. Net income forecast to grow 6.2% next year vs 6.9% growth forecast for Healthcare industry in Japan. Consensus price target up from JP¥4,200 to JP¥4,500. Share price fell 5.4% to JP¥4,065 over the past week. Reported Earnings • Feb 07
Third quarter 2026 earnings released: EPS: JP¥62.19 (vs JP¥47.02 in 3Q 2025) Third quarter 2026 results: EPS: JP¥62.19 (up from JP¥47.02 in 3Q 2025). Revenue: JP¥38.8b (up 4.4% from 3Q 2025). Net income: JP¥2.34b (up 28% from 3Q 2025). Profit margin: 6.0% (up from 4.9% in 3Q 2025). The increase in margin was driven by higher revenue. Revenue is forecast to grow 3.1% p.a. on average during the next 3 years, compared to a 3.8% growth forecast for the Healthcare industry in Japan. Over the last 3 years on average, earnings per share has fallen by 40% per year but the company’s share price has increased by 8% per year, which means it is well ahead of earnings. Declared Dividend • Dec 03
First half dividend of JP¥60.00 announced Shareholders will receive a dividend of JP¥60.00. Ex-date: 30th March 2026 Payment date: 30th June 2026 Dividend yield will be 3.1%, which is higher than the industry average of 2.2%. Sustainability & Growth Dividend is covered by both earnings (27% earnings payout ratio) and cash flows (50% cash payout ratio). The dividend has increased by an average of 15% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. EPS is expected to grow by 31% over the next 3 years, which should provide support to the dividend and adequate earnings cover. Reported Earnings • Nov 08
Second quarter 2026 earnings released: EPS: JP¥61.81 (vs JP¥44.08 in 2Q 2025) Second quarter 2026 results: EPS: JP¥61.81 (up from JP¥44.08 in 2Q 2025). Revenue: JP¥37.6b (up 5.1% from 2Q 2025). Net income: JP¥2.36b (up 37% from 2Q 2025). Profit margin: 6.3% (up from 4.8% in 2Q 2025). The increase in margin was driven by higher revenue. Revenue is forecast to grow 3.2% p.a. on average during the next 3 years, compared to a 4.3% growth forecast for the Healthcare industry in Japan. Over the last 3 years on average, earnings per share has fallen by 53% per year but the company’s share price has increased by 4% per year, which means it is well ahead of earnings. Upcoming Dividend • Sep 22
Upcoming dividend of JP¥60.00 per share Eligible shareholders must have bought the stock before 29 September 2025. Payment date: 03 December 2025. Payout ratio is a comfortable 61% but the company is not cash flow positive. Trailing yield: 3.2%. Lower than top quartile of Japanese dividend payers (3.6%). Higher than average of industry peers (2.6%). Reported Earnings • Aug 09
First quarter 2026 earnings released: EPS: JP¥47.74 (vs JP¥43.79 in 1Q 2025) First quarter 2026 results: EPS: JP¥47.74 (up from JP¥43.79 in 1Q 2025). Revenue: JP¥38.0b (up 6.8% from 1Q 2025). Net income: JP¥1.86b (up 9.1% from 1Q 2025). Profit margin: 4.9% (up from 4.8% in 1Q 2025). The increase in margin was driven by higher revenue. Revenue is forecast to grow 3.3% p.a. on average during the next 3 years, compared to a 4.4% growth forecast for the Healthcare industry in Japan. Over the last 3 years on average, earnings per share has fallen by 60% per year but the company’s share price has only fallen by 3% per year, which means it has not declined as severely as earnings. Declared Dividend • Jul 09
Final dividend increased to JP¥60.00 Dividend of JP¥60.00 is 20% higher than last year. Ex-date: 29th September 2025 Payment date: 3rd December 2025 Dividend yield will be 3.9%, which is higher than the industry average of 2.2%. Sustainability & Growth Dividend is covered by earnings (58% earnings payout ratio) but the company has no free cash flows available, indicating it may be using cash reserves or debt to pay the dividend. The dividend has increased by an average of 15% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. EPS is expected to grow by 37% over the next 3 years, which should provide support to the dividend and adequate earnings cover. Reported Earnings • Jun 30
Full year 2025 earnings: EPS exceeds analyst expectations Full year 2025 results: EPS: JP¥161 (up from JP¥155 in FY 2024). Revenue: JP¥143.2b (up 3.8% from FY 2024). Net income: JP¥6.26b (up 3.8% from FY 2024). Profit margin: 4.4% (in line with FY 2024). Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 2.8%. Revenue is forecast to grow 3.5% p.a. on average during the next 3 years, compared to a 4.5% growth forecast for the Healthcare industry in Japan. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 63 percentage points per year, which is a significant difference in performance. Major Estimate Revision • Jun 06
Consensus EPS estimates increase by 15% The consensus outlook for fiscal year 2026 has been updated. 2026 EPS estimate increased from JP¥149 to JP¥171. Revenue forecast steady at JP¥148.0b. Net income forecast to grow 3.8% next year vs 8.2% growth forecast for Healthcare industry in Japan. Consensus price target up from JP¥2,900 to JP¥4,200. Share price rose 11% to JP¥3,340 over the past week. Price Target Changed • Jun 05
Price target increased by 38% to JP¥4,200 Up from JP¥3,033, the current price target is provided by 1 analyst. New target price is 38% above last closing price of JP¥3,040. Stock is up 9.4% over the past year. The company is forecast to post earnings per share of JP¥171 for next year compared to JP¥161 last year. Announcement • Jun 03
BML, Inc. to Report Q1, 2026 Results on Aug 08, 2025 BML, Inc. announced that they will report Q1, 2026 results on Aug 08, 2025 Reported Earnings • May 10
Full year 2025 earnings: EPS exceeds analyst expectations Full year 2025 results: EPS: JP¥161 (up from JP¥155 in FY 2024). Revenue: JP¥143.2b (up 3.8% from FY 2024). Net income: JP¥6.26b (up 3.8% from FY 2024). Profit margin: 4.4% (in line with FY 2024). Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 2.8%. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 61 percentage points per year, which is a significant difference in performance. Announcement • May 09
BML, Inc., Annual General Meeting, Jun 27, 2025 BML, Inc., Annual General Meeting, Jun 27, 2025. Upcoming Dividend • Mar 21
Upcoming dividend of JP¥70.00 per share Eligible shareholders must have bought the stock before 28 March 2025. Payment date: 30 June 2025. Payout ratio is a comfortable 26% but the company is not cash flow positive. Trailing yield: 4.7%. Within top quartile of Japanese dividend payers (3.7%). Higher than average of industry peers (2.7%). Announcement • Mar 04
BML, Inc. to Report Fiscal Year 2025 Results on May 09, 2025 BML, Inc. announced that they will report fiscal year 2025 results on May 09, 2025 New Risk • Feb 13
New major risk - Revenue and earnings growth Earnings are forecast to decline by an average of 1.2% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 1.2% per year for the foreseeable future. Minor Risk Paying a dividend despite having no free cash flows. Reported Earnings • Feb 08
Third quarter 2025 earnings released: EPS: JP¥47.02 (vs JP¥47.58 in 3Q 2024) Third quarter 2025 results: EPS: JP¥47.02 (down from JP¥47.58 in 3Q 2024). Revenue: JP¥37.2b (up 6.0% from 3Q 2024). Net income: JP¥1.83b (down 1.1% from 3Q 2024). Profit margin: 4.9% (down from 5.3% in 3Q 2024). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 1.8% p.a. on average during the next 3 years, compared to a 4.7% growth forecast for the Healthcare industry in Japan. Over the last 3 years on average, earnings per share has fallen by 62% per year but the company’s share price has only fallen by 8% per year, which means it has not declined as severely as earnings. New Risk • Nov 09
New major risk - Revenue and earnings growth Earnings are forecast to decline by an average of 0.2% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 0.2% per year for the foreseeable future. Minor Risk Paying a dividend despite having no free cash flows. Reported Earnings • Nov 09
Second quarter 2025 earnings released: EPS: JP¥44.08 (vs JP¥40.00 in 2Q 2024) Second quarter 2025 results: EPS: JP¥44.08 (up from JP¥40.00 in 2Q 2024). Revenue: JP¥35.8b (up 2.7% from 2Q 2024). Net income: JP¥1.72b (up 10% from 2Q 2024). Profit margin: 4.8% (up from 4.5% in 2Q 2024). The increase in margin was driven by higher revenue. Revenue is forecast to grow 2.5% p.a. on average during the next 3 years, compared to a 5.3% growth forecast for the Healthcare industry in Japan. Over the last 3 years on average, earnings per share has fallen by 57% per year but the company’s share price has only fallen by 10% per year, which means it has not declined as severely as earnings. Upcoming Dividend • Sep 20
Upcoming dividend of JP¥50.00 per share Eligible shareholders must have bought the stock before 27 September 2024. Payment date: 04 December 2024. Payout ratio is a comfortable 52% but the company is not cash flow positive. Trailing yield: 3.7%. Lower than top quartile of Japanese dividend payers (3.8%). Higher than average of industry peers (2.3%). Reported Earnings • Aug 13
First quarter 2025 earnings released: EPS: JP¥43.79 (vs JP¥46.08 in 1Q 2024) First quarter 2025 results: EPS: JP¥43.79 (down from JP¥46.08 in 1Q 2024). Revenue: JP¥35.6b (flat on 1Q 2024). Net income: JP¥1.71b (down 5.0% from 1Q 2024). Profit margin: 4.8% (down from 5.1% in 1Q 2024). Revenue is forecast to grow 2.5% p.a. on average during the next 3 years, compared to a 5.4% growth forecast for the Healthcare industry in Japan. Over the last 3 years on average, earnings per share has fallen by 47% per year but the company’s share price has only fallen by 17% per year, which means it has not declined as severely as earnings. Announcement • Jun 06
BML, Inc. to Report Q1, 2025 Results on Aug 09, 2024 BML, Inc. announced that they will report Q1, 2025 results on Aug 09, 2024 Reported Earnings • May 12
Full year 2024 earnings: EPS exceeds analyst expectations Full year 2024 results: EPS: JP¥155 (down from JP¥396 in FY 2023). Revenue: JP¥138.0b (down 14% from FY 2023). Net income: JP¥6.03b (down 61% from FY 2023). Profit margin: 4.4% (down from 9.8% in FY 2023). The decrease in margin was driven by lower revenue. Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 2.9%. Revenue is forecast to grow 2.4% p.a. on average during the next 3 years, compared to a 5.4% growth forecast for the Healthcare industry in Japan. Over the last 3 years on average, earnings per share has fallen by 32% per year but the company’s share price has only fallen by 6% per year, which means it has not declined as severely as earnings. Announcement • May 12
BML, Inc., Annual General Meeting, Jun 27, 2024 BML, Inc., Annual General Meeting, Jun 27, 2024. Price Target Changed • May 10
Price target decreased by 8.2% to JP¥2,967 Down from JP¥3,233, the current price target is an average from 3 analysts. New target price is approximately in line with last closing price of JP¥3,020. Stock is down 1.8% over the past year. The company is forecast to post earnings per share of JP¥150 for next year compared to JP¥396 last year. Upcoming Dividend • Mar 21
Upcoming dividend of JP¥40.00 per share Eligible shareholders must have bought the stock before 28 March 2024. Payment date: 01 July 2024. Payout ratio is a comfortable 42% but the company is paying out more than the cash it is generating. Trailing yield: 2.7%. Lower than top quartile of Japanese dividend payers (3.2%). Higher than average of industry peers (2.2%). Announcement • Mar 02
BML, Inc. to Report Fiscal Year 2024 Results on May 10, 2024 BML, Inc. announced that they will report fiscal year 2024 results on May 10, 2024 Price Target Changed • Feb 13
Price target decreased by 7.4% to JP¥3,033 Down from JP¥3,275, the current price target is an average from 3 analysts. New target price is 13% above last closing price of JP¥2,686. Stock is down 13% over the past year. The company is forecast to post earnings per share of JP¥175 for next year compared to JP¥396 last year. New Risk • Feb 13
New major risk - Revenue and earnings growth Earnings are forecast to decline by an average of 1.7% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 1.7% per year for the foreseeable future. Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Profit margins are more than 30% lower than last year (5.3% net profit margin). Reported Earnings • Feb 10
Third quarter 2024 earnings released: EPS: JP¥47.58 (vs JP¥76.57 in 3Q 2023) Third quarter 2024 results: EPS: JP¥47.58 (down from JP¥76.57 in 3Q 2023). Revenue: JP¥35.1b (down 13% from 3Q 2023). Net income: JP¥1.86b (down 38% from 3Q 2023). Profit margin: 5.3% (down from 7.5% in 3Q 2023). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 1.4% p.a. on average during the next 3 years, compared to a 5.3% growth forecast for the Healthcare industry in Japan. Over the last 3 years on average, earnings per share has fallen by 14% per year whereas the company’s share price has fallen by 11% per year. New Risk • Dec 16
New major risk - Revenue and earnings growth Earnings are forecast to decline by an average of 3.0% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 3.0% per year for the foreseeable future. Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Profit margins are more than 30% lower than last year (5.9% net profit margin). Price Target Changed • Dec 07
Price target decreased by 7.2% to JP¥3,225 Down from JP¥3,475, the current price target is an average from 4 analysts. New target price is 8.3% above last closing price of JP¥2,978. Stock is down 9.6% over the past year. The company is forecast to post earnings per share of JP¥187 for next year compared to JP¥396 last year. Reported Earnings • Nov 11
Second quarter 2024 earnings released: EPS: JP¥40.00 (vs JP¥143 in 2Q 2023) Second quarter 2024 results: EPS: JP¥40.00 (down from JP¥143 in 2Q 2023). Revenue: JP¥34.8b (down 19% from 2Q 2023). Net income: JP¥1.56b (down 72% from 2Q 2023). Profit margin: 4.5% (down from 13% in 2Q 2023). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 3.2% p.a. on average during the next 3 years, compared to a 5.9% growth forecast for the Healthcare industry in Japan. Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has fallen by 4% per year, which means it is significantly lagging earnings. Price Target Changed • Oct 05
Price target decreased by 7.1% to JP¥3,275 Down from JP¥3,525, the current price target is an average from 4 analysts. New target price is 15% above last closing price of JP¥2,845. Stock is down 15% over the past year. The company is forecast to post earnings per share of JP¥192 for next year compared to JP¥396 last year. Upcoming Dividend • Sep 21
Upcoming dividend of JP¥40.00 per share at 2.9% yield Eligible shareholders must have bought the stock before 28 September 2023. Payment date: 04 December 2023. Payout ratio is a comfortable 25% and the cash payout ratio is 94%. Trailing yield: 2.9%. Lower than top quartile of Japanese dividend payers (3.3%). Higher than average of industry peers (2.1%). Announcement • Aug 30
BML, Inc. to Report Q2, 2024 Results on Feb 09, 2024 BML, Inc. announced that they will report Q2, 2024 results on Feb 09, 2024 Price Target Changed • Aug 14
Price target decreased by 8.2% to JP¥3,525 Down from JP¥3,840, the current price target is an average from 4 analysts. New target price is 33% above last closing price of JP¥2,660. Stock is down 32% over the past year. The company is forecast to post earnings per share of JP¥215 for next year compared to JP¥396 last year. Reported Earnings • Aug 12
First quarter 2024 earnings released: EPS: JP¥46.08 (vs JP¥119 in 1Q 2023) First quarter 2024 results: EPS: JP¥46.08 (down from JP¥119 in 1Q 2023). Revenue: JP¥35.3b (down 13% from 1Q 2023). Net income: JP¥1.80b (down 62% from 1Q 2023). Profit margin: 5.1% (down from 12% in 1Q 2023). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 1.7% p.a. on average during the next 3 years, compared to a 5.8% growth forecast for the Healthcare industry in Japan. Over the last 3 years on average, earnings per share has increased by 24% per year but the company’s share price has only increased by 2% per year, which means it is significantly lagging earnings growth. Price Target Changed • Jun 07
Price target decreased by 7.1% to JP¥3,740 Down from JP¥4,025, the current price target is an average from 5 analysts. New target price is 19% above last closing price of JP¥3,140. Stock is down 12% over the past year. The company is forecast to post earnings per share of JP¥215 for next year compared to JP¥396 last year. Announcement • May 31
BML, Inc. to Report Q1, 2024 Results on Aug 10, 2023 BML, Inc. announced that they will report Q1, 2024 results on Aug 10, 2023 Reported Earnings • May 16
Full year 2023 earnings: EPS and revenues exceed analyst expectations Full year 2023 results: EPS: JP¥396 (down from JP¥833 in FY 2022). Revenue: JP¥159.5b (down 14% from FY 2022). Net income: JP¥15.6b (down 54% from FY 2022). Profit margin: 9.8% (down from 18% in FY 2022). The decrease in margin was driven by lower revenue. Revenue exceeded analyst estimates by 1.7%. Earnings per share (EPS) also surpassed analyst estimates by 4.2%. Revenue is forecast to stay flat during the next 3 years compared to a 5.1% growth forecast for the Healthcare industry in Japan. Over the last 3 years on average, earnings per share has increased by 39% per year but the company’s share price has only increased by 4% per year, which means it is significantly lagging earnings growth. Announcement • May 14
BML, Inc., Annual General Meeting, Jun 29, 2023 BML, Inc., Annual General Meeting, Jun 29, 2023. Upcoming Dividend • Mar 23
Upcoming dividend of JP¥60.00 per share at 2.6% yield Eligible shareholders must have bought the stock before 30 March 2023. Payment date: 30 June 2023. Payout ratio is a comfortable 15% and this is well supported by cash flows. Trailing yield: 2.6%. Lower than top quartile of Japanese dividend payers (3.6%). Higher than average of industry peers (2.3%). Reported Earnings • Feb 12
Third quarter 2023 earnings released: EPS: JP¥76.57 (vs JP¥131 in 3Q 2022) Third quarter 2023 results: EPS: JP¥76.57 (down from JP¥131 in 3Q 2022). Revenue: JP¥40.2b (down 1.9% from 3Q 2022). Net income: JP¥3.01b (down 43% from 3Q 2022). Profit margin: 7.5% (down from 13% in 3Q 2022). The decrease in margin was primarily driven by higher expenses. Revenue is forecast to stay flat during the next 3 years compared to a 5.9% growth forecast for the Healthcare industry in Japan. Over the last 3 years on average, earnings per share has increased by 52% per year but the company’s share price has fallen by 2% per year, which means it is significantly lagging earnings. Announcement • Feb 11
BML, Inc. (TSE:4694) announces an Equity Buyback for 350,000 shares, representing 0.89% for ¥1,000 million. BML, Inc. (TSE:4694) announces a share repurchase program. Under the program, the company will repurchase up to 350,000 shares, representing 0.89% of its issued share capital for ¥1,000 million. The purpose of the program is to improve capital efficiency and enhance shareholder returns. The program is valid till April 30, 2023. As of January 31, 2023, the company had 39,279,662 shares issued (excluding treasury stock) and 3,333,964 shares in treasury. Board Change • Nov 16
Less than half of directors are independent Following the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 6 non-independent directors. Independent Outside Director Shigeru Osawa was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Reported Earnings • Nov 13
Second quarter 2023 earnings released: EPS: JP¥143 (vs JP¥217 in 2Q 2022) Second quarter 2023 results: EPS: JP¥143 (down from JP¥217 in 2Q 2022). Revenue: JP¥43.2b (down 11% from 2Q 2022). Net income: JP¥5.61b (down 36% from 2Q 2022). Profit margin: 13% (down from 18% in 2Q 2022). The decrease in margin was driven by lower revenue. Revenue is forecast to stay flat during the next 3 years compared to a 5.3% growth forecast for the Healthcare industry in Japan. Over the last 3 years on average, earnings per share has increased by 61% per year but the company’s share price has only increased by 2% per year, which means it is significantly lagging earnings growth. Major Estimate Revision • Oct 28
Consensus EPS estimates increase by 10% The consensus outlook for earnings per share (EPS) in 2023 has improved. 2023 revenue forecast increased from JP¥147.0b to JP¥151.1b. EPS estimate increased from JP¥303 to JP¥335 per share. Net income forecast to shrink 57% next year vs 14% growth forecast for Healthcare industry in Japan . Consensus price target of JP¥4,328 unchanged from last update. Share price was steady at JP¥3,370 over the past week. Upcoming Dividend • Sep 22
Upcoming dividend of JP¥40.00 per share Eligible shareholders must have bought the stock before 29 September 2022. Payment date: 02 December 2022. Payout ratio is a comfortable 17% and this is well supported by cash flows. Trailing yield: 2.4%. Lower than top quartile of Japanese dividend payers (3.7%). In line with average of industry peers (2.2%). Announcement • Aug 31
BML, Inc. to Report Q3, 2023 Results on Feb 10, 2023 BML, Inc. announced that they will report Q3, 2023 results on Feb 10, 2023 Reported Earnings • Aug 12
First quarter 2023 earnings released: EPS: JP¥119 (vs JP¥244 in 1Q 2022) First quarter 2023 results: EPS: JP¥119 (down from JP¥244 in 1Q 2022). Revenue: JP¥40.5b (down 14% from 1Q 2022). Net income: JP¥4.72b (down 53% from 1Q 2022). Profit margin: 12% (down from 21% in 1Q 2022). The decrease in margin was driven by lower revenue. Over the next year, revenue is expected to shrink by 20% compared to a 4.6% growth forecast for the industry in Japan. Over the last 3 years on average, earnings per share has increased by 67% per year but the company’s share price has only increased by 9% per year, which means it is significantly lagging earnings growth. Price Target Changed • May 19
Price target decreased to JP¥4,075 Down from JP¥4,500, the current price target is an average from 4 analysts. New target price is 21% above last closing price of JP¥3,365. Stock is down 9.2% over the past year. The company is forecast to post earnings per share of JP¥270 for next year compared to JP¥833 last year. Reported Earnings • May 17
Full year 2022 earnings: EPS misses analyst expectations Full year 2022 results: EPS: JP¥833 (up from JP¥337 in FY 2021). Revenue: JP¥186.1b (up 34% from FY 2021). Net income: JP¥33.7b (up 146% from FY 2021). Profit margin: 18% (up from 9.9% in FY 2021). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 1.3%. Over the next year, revenue is expected to shrink by 24% compared to a 4.2% growth forecast for the industry in Japan. Over the last 3 years on average, earnings per share has increased by 69% per year but the company’s share price has only increased by 2% per year, which means it is significantly lagging earnings growth. Board Change • Apr 27
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. 3 highly experienced directors. 3 independent directors (5 non-independent directors). Managing Executive Officer & Director Masato Chikira was the last director to join the board, commencing their role in 2012. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Upcoming Dividend • Mar 23
Upcoming dividend of JP¥85.00 per share Eligible shareholders must have bought the stock before 30 March 2022. Payment date: 30 June 2022. Payout ratio is a comfortable 12% and this is well supported by cash flows. Trailing yield: 2.2%. Lower than top quartile of Japanese dividend payers (3.4%). In line with average of industry peers (2.0%). Price Target Changed • Mar 09
Price target decreased to JP¥4,325 Down from JP¥4,667, the current price target is an average from 4 analysts. New target price is 41% above last closing price of JP¥3,075. Stock is down 14% over the past year. The company is forecast to post earnings per share of JP¥695 for next year compared to JP¥337 last year. Reported Earnings • Feb 10
Third quarter 2022 earnings: EPS and revenues exceed analyst expectations Third quarter 2022 results: EPS: JP¥131 (up from JP¥126 in 3Q 2021). Revenue: JP¥41.0b (up 6.6% from 3Q 2021). Net income: JP¥5.29b (up 3.1% from 3Q 2021). Profit margin: 13% (in line with 3Q 2021). Revenue exceeded analyst estimates by 7.7%. Earnings per share (EPS) also surpassed analyst estimates by 8.0%. Over the next year, revenue is expected to shrink by 18% compared to a 4.9% growth forecast for the industry in Japan. Over the last 3 years on average, earnings per share has increased by 65% per year but the company’s share price has only increased by 3% per year, which means it is significantly lagging earnings growth. Reported Earnings • Nov 12
Second quarter 2022 earnings released: EPS JP¥217 (vs JP¥83.75 in 2Q 2021) The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2022 results: Revenue: JP¥48.6b (up 44% from 2Q 2021). Net income: JP¥8.82b (up 159% from 2Q 2021). Profit margin: 18% (up from 10% in 2Q 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 57% per year but the company’s share price has only increased by 11% per year, which means it is significantly lagging earnings growth. Price Target Changed • Oct 07
Price target increased to JP¥5,200 Up from JP¥4,833, the current price target is an average from 3 analysts. New target price is 29% above last closing price of JP¥4,040. Stock is up 24% over the past year. Upcoming Dividend • Sep 22
Upcoming dividend of JP¥35.00 per share Eligible shareholders must have bought the stock before 29 September 2021. Payment date: 02 December 2021. Trailing yield: 1.6%. Lower than top quartile of Japanese dividend payers (3.0%). Lower than average of industry peers (1.8%). Price Target Changed • Sep 06
Price target increased to JP¥5,033 Up from JP¥4,700, the current price target is an average from 3 analysts. New target price is 14% above last closing price of JP¥4,410. Stock is up 53% over the past year. Major Estimate Revision • Aug 18
Consensus EPS estimates increase to JP¥490 The consensus outlook for earnings per share (EPS) in 2022 has improved. 2022 revenue forecast increased from JP¥146.9b to JP¥155.5b. EPS estimate increased from JP¥369 to JP¥490 per share. Net income forecast to shrink 25% next year vs 15% growth forecast for Healthcare industry in Japan . Consensus price target up from JP¥4,700 to JP¥4,833. Share price rose 13% to JP¥4,710 over the past week. Reported Earnings • Aug 13
First quarter 2022 earnings released: EPS JP¥244 (vs JP¥2.73 in 1Q 2021) The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2022 results: Revenue: JP¥47.1b (up 80% from 1Q 2021). Net income: JP¥9.94b (up JP¥9.83b from 1Q 2021). Profit margin: 21% (up from 0.4% in 1Q 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 41% per year but the company’s share price has only increased by 16% per year, which means it is significantly lagging earnings growth. Valuation Update With 7 Day Price Move • Aug 13
Investor sentiment improved over the past week After last week's 22% share price gain to JP¥4,870, the stock trades at a forward P/E ratio of 13x. Average forward P/E is 18x in the Healthcare industry in Japan. Total returns to shareholders of 64% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at JP¥6,869 per share. Reported Earnings • May 15
Full year 2021 earnings released: EPS JP¥337 (vs JP¥151 in FY 2020) The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2021 results: Revenue: JP¥138.6b (up 15% from FY 2020). Net income: JP¥13.7b (up 115% from FY 2020). Profit margin: 9.9% (up from 5.3% in FY 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 19% per year but the company’s share price has only increased by 10% per year, which means it is significantly lagging earnings growth. Price Target Changed • Apr 01
Price target increased to JP¥4,700 Up from JP¥4,367, the current price target is an average from 3 analysts. New target price is 21% above last closing price of JP¥3,900. Stock is up 49% over the past year. Upcoming Dividend • Mar 23
Upcoming dividend of JP¥50.00 per share Eligible shareholders must have bought the stock before 30 March 2021. Payment date: 29 June 2021. Trailing yield: 1.4%. Lower than top quartile of Japanese dividend payers (2.7%). In line with average of industry peers (1.5%). Major Estimate Revision • Mar 03
Analysts increase EPS estimates to JP¥256 The 2021 consensus revenue estimate increased from JP¥128.9b to JP¥131.5b. The earnings per share estimate also received an upgrade from JP¥232 to JP¥256 for the same period. Net income is expected to grow by 15% next year compared to 9.8% growth forecast for the Healthcare industry in Japan. The consensus price target increased from JP¥4,267 to JP¥4,367. Share price is up 1.4% to JP¥3,650 over the past week. Price Target Changed • Feb 17
Price target raised to JP¥4,267 Up from JP¥3,733, the current price target is an average from 3 analysts. The new target price is 14% above the current share price of JP¥3,730. As of last close, the stock is up 17% over the past year. Reported Earnings • Feb 12
Third quarter 2021 earnings released: EPS JP¥126 (vs JP¥40.86 in 3Q 2020) The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: JP¥38.5b (up 24% from 3Q 2020). Net income: JP¥5.14b (up 195% from 3Q 2020). Profit margin: 13% (up from 5.6% in 3Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 6% per year but the company’s share price has increased by 16% per year, which means it is tracking significantly ahead of earnings growth. Analyst Estimate Surprise Post Earnings • Feb 12
Revenue and earnings beat expectations Revenue exceeded analyst estimates by 11%. Earnings per share (EPS) also surpassed analyst estimates by 2.3%. Over the next year, revenue is forecast to grow 1.5%, compared to a 7.5% growth forecast for the Healthcare industry in Japan. Is New 90 Day High Low • Feb 10
New 90-day high: JP¥3,840 The company is up 21% from its price of JP¥3,170 on 12 November 2020. The Japanese market is up 11% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare industry, which is up 12% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is JP¥4,703 per share. Is New 90 Day High Low • Jan 21
New 90-day high: JP¥3,640 The company is up 22% from its price of JP¥2,994 on 23 October 2020. The Japanese market is up 13% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare industry, which is up 8.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is JP¥4,703 per share. Major Estimate Revision • Jan 08
Analysts increase EPS estimates to JP¥220 The 2021 consensus revenue estimate increased from JP¥124.3b to JP¥126.7b. The earnings per share estimate also received an upgrade from JP¥180 to JP¥220 for the same period. Net income is expected to grow by 52% next year compared to 13% growth forecast for the Healthcare industry in Japan. The consensus price target increased from JP¥3,733 to JP¥3,867. Share price is up 8.1% to JP¥3,465 over the past week. Is New 90 Day High Low • Dec 09
New 90-day high: JP¥3,415 The company is up 17% from its price of JP¥2,913 on 10 September 2020. The Japanese market is up 9.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare industry, which is up 4.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is JP¥3,974 per share. Major Estimate Revision • Dec 01
Analysts increase EPS estimates to JP¥175 The 2021 consensus revenue estimate increased from JP¥122.0b to JP¥123.8b. The earnings per share estimate also received an upgrade from JP¥149 to JP¥175 for the same period. Net income is expected to grow by 26% next year compared to 9.2% growth forecast for the Healthcare industry in Japan. The consensus price target increased from JP¥3,280 to JP¥3,533. Share price is down by 2.5% to JP¥3,305 over the past week. Price Target Changed • Dec 01
Price target raised to JP¥3,533 Up from JP¥3,280, the current price target is an average from 3 analysts. The new target price is 6.9% above the current share price of JP¥3,305. As of last close, the stock is up 3.3% over the past year. 
